NCT06961786View on ClinicalTrials.gov

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

April 30, 2027

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

BIOLOGICAL

TIL

Adoptive T cell therapy with TILs

DRUG

Cyclophosphamide

Lymphocyte-depleting chemotherapy

DRUG

Fludarabine

Lymphocyte-depleting chemotherapy

Trial Locations (1)

Unknown

RECRUITING

National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University, Copenhagen

All Listed Sponsors
lead

TILT Biotherapeutics Ltd.

INDUSTRY